Useful links
• Affymetrix, the manufacturer of the DNA microarrays used by HaploPharma for ExpressGenotyping™ studies
• Center of Molecular Biosciences, University of the Ryukyus
• European Medicines Agency (EMA), the EU regulatory agency for the evaluation of medicinal products
• The International HapMap Project is an organization whose goal is to develop a haplotype map of the human genome (HapMap), which will describe the common patterns of human genetic variation. The HapMap is expected to be a key resource for researchers to find genetic variants affecting health, disease and responses to drugs and environmental factors.
• The International Serious Adverse Event Consortium [SAEC] is a nonprofit organization comprised of leading pharmaceutical companies and academic institutions with scientific and strategic input from the U.S. Food and Drug Administration (FDA). The mission of the SAEC is to help identify and validate DNA-variants useful in predicting the risk of drug-related serious adverse events (SAEs).
• Okinawa Health Biotechnology Research and Development Center (Japanese home page). In this center HaploPharma’s Okinawa research facilities are located.
• Okinawa Industry Promotion Public Corporation
• Okinawa Institute of Science and Technology
• Homepage of Okinawa prefecture
• Pharmacogenomics - Medicine and the new genetics from the Human Genome Project
• PharmGKB, the Pharmacogenetics and Pharmacogenomics Knowledge Base
• Pharmaceuticals and Medical Devices Agency (PMDA), the Japanese regulatory body for the evaluation of medicinal products
• Ryukyu Islands (Okinawa) at Wikipedia
• The Single Nucleotide Polymorphism database (dbSNP) is a public-domain archive for a broad collection of Single Nucleotide Polymorphisms (SNPs) as well as small insertion/deletions (indels) and is hosted at the U.S. National Center for Biotechnology Information (NCBI).
• FDA’s (U.S. Food and Drug Administration) Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels